<?xml version="1.0" encoding="UTF-8"?>
<p id="p0070">The safety of the use of CP is another issue that has been historically relevant in epidemics. Currently, evidence exists of the safety of CP in situations of emergency (
 <xref rid="t0010" ref-type="table">Table 2</xref>). In epidemics of Influenza A (H1N1), SARS-CoV and MERS-CoV, studies did not find any adverse event associated to CP administration. In the case of Ebola, CP administration was associated with mild adverse reactions such as nausea, skin erythema, and fever [
 <xref rid="bb0125" ref-type="bibr">25</xref>]. In COVID-19, reports have shown that administration of CP is safe, and it was not associated with major adverse events. Thus, due to tolerability and potential efficacy, CP is a good candidate to be evaluated as a therapeutic option to control the current pandemic.
</p>
